This study is not yet accepting patients
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Celgene
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
- ID
- NCT06232707
- Phase
- Phase 3 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- Expecting 466 study participants
- Last Updated